Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer
NCT ID: NCT05670457
Last Updated: 2023-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
44 participants
INTERVENTIONAL
2022-06-30
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
NCT02418312
DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers
NCT02262169
High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment
NCT00709046
Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers
NCT03163680
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
NCT02551744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
this group will include 22 patients who will receive anti peptic ulcer only for 2 months.
No interventions assigned to this group
Diosmin group
this group will include 22 patients who will receive anti peptic ulcer and diosmin 500 mg twice daily for 2 months.
Diosmin
diosmin 500 mg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diosmin
diosmin 500 mg twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of both gender (male and female).
* Non-bleeding Peptic ulcer Patients (duodenal \&gastric) diagnosed by endoscopy.
Exclusion Criteria
* Patients with cancerous disease
* Breast-feeding.
* Surgically altered stomach ( bariatric surgery),
* Patient with liver disease.
* Bleeding \& perforated peptic ulcer.
25 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Gamal Salah Abdelfatah
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
diosmin peptic ulcer
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.